Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study - Report - MDSpire
Advertisement
Healthcare utilization and costs in patients with rheumatoid arthritis using biologics or tofacitinib: a nationwide, population-based study
Utilization of Healthcare Resources and Associated Costs in Rheumatoid Arthritis Patients Treated with Biologics or Tofacitinib
Overview
This nationwide analysis evaluates healthcare utilization and costs associated with rheumatoid arthritis patients in Taiwan treated with biologics or tofacitinib.
Background
Rheumatoid arthritis (RA) is a prevalent chronic inflammatory disease that leads to joint damage and increased healthcare costs. The introduction of biologic agents has transformed RA management, yet the economic impact and resource utilization patterns remain underexplored, particularly in Taiwan's unique healthcare system.
Data Highlights
No numerical data available in the provided material.
Key Findings
RA is a chronic disease with a prevalence of 0.3 to 1% globally, more common in females.
Biologics have improved clinical outcomes in RA patients, but their high costs raise concerns for healthcare systems.
In Taiwan, RA patients can access biologics without additional payment after failing two csDMARDs.
There is a lack of comprehensive evaluation of healthcare resource utilization patterns for RA patients treated with various biologics and tofacitinib.
Clinical Implications
Healthcare providers should be aware of the rising costs associated with biologic treatments for RA and the potential for reduced overall healthcare expenditures due to decreased hospitalization rates. Policymakers need to consider these factors when developing strategies for RA management within the healthcare system.
Conclusion
This study evaluates healthcare resource utilization and costs in RA patients receiving biologic therapies.
